Pfizer
Pfizer’s leukaemia drug gets opposing regulatory decisions on either side of the Atlantic
August 18, 2017Medical Communications, Sales and Marketing Besponsa, Cancer, FDA, NICE, Pfizer, leukaemia, pharma, pharmaceutical
Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval …
Pfizer’s major drug doubles sales but overall revenue falls
August 1, 2017Research and Development, Sales and Marketing Bavencio, Pfizer, biotech, drugs, pharma, pharmaceutical, viagra
Pfizer revealed in its briefing on its second quarter financials that Ibrance, its breast cancer treatment, had grown in sales …
Biogen steal away Pfizer VP to boost R&D plans
August 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer has had a tough time keeping hold of its Vice President’s involved in R&D of late, losing high-profile researcher, …
GSK completes further high-profile staff acquisition
July 17, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer Senior Vice President of Medicinal Sciences, Tony Wood, has agreed to join GSK, as broken by FierceBiotech. The appointment …
Regulators get aggressive on matters excessive
June 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CMA, Drug pricing, European Commission, Pfizer, aspen
Gustaf Duhs, Partner at Stevens & Bolton, discusses the recent cases of regulators becoming firmer with drug companies over their …
Pfizer’s biosimilar gets a second knock-back from FDA
June 23, 2017Medical Communications, Sales and Marketing Amgen, Epogen, FDA, Pfizer
Pfizer has been dealt a stinging blow by the FDA, after it received a second complete response letter from the …
Pfizer launches vaccine study in Group B Streptococcus
June 20, 2017Manufacturing and Production, Research and Development Group B Streptococcus, Pfizer
A potentially pivotal Phase 1 study has been launched by Pfizer into the use of its investigational vaccine as a …
FDA fast-tracks Pfizer and Lilly’s chronic pain drug
June 15, 2017Research and Development, Sales and Marketing Eli Lilly, FDA, Pfizer
Pfizer and Eli Lilly are celebrating the FDA’s decision to grant fast-track designation to their joint venture tanezumab in the …
Pfizer gets fast-track approval for rare heart condition
June 8, 2017Sales and Marketing Pfizer
Pfizer’s tafamidis has already been given approval in 40 countries across the globe but it has not currently broken into …
Pfizer drug beats AZ rival in halting lung cancer
June 6, 2017Manufacturing and Production, Research and Development NSCLC, Pfizer
New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression …
Shortage of medicine made of kitchen basics hits US
May 23, 2017Manufacturing and Production Pfizer, Sodium bicarbonate
Do you have a pot of unused baking soda that sits at the back of the cupboard, forgotten? Well, hospitals …
70 patients sue Pfizer over arthritis drug risks
May 22, 2017Sales and Marketing Pfizer, celebrex
Pfizer has been hit with a £3.5 million lawsuit by 70 Scottish patients who claim that the use of its …
Sangamo secures FDA’s Fast Track Designation for haemophilia candidate
May 17, 2017Research and Development, Sales and Marketing FDA, Pfizer, Sangamo Therapeutics
Sangamo Therapeutics has announced that the FDA has granted its cDNA gene therapy candidate for haemophilia A Fast Track Designation. …
India to immunise five million using Pfizer pneumococcal disease vaccine
May 15, 2017Sales and Marketing 13-valent Pneumococcal Conjugate Vaccine, India, PCV 13, Pfizer
An Indian immunisation programme will make use of Pfizer’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) to treat around 5.15 million, …
Pfizer offers breast cancer drug for free following NICE rejection
May 5, 2017Medical Communications, Sales and Marketing NICE, Pfizer
Following NICE’s decision rejecting Pfizer’s breast cancer therapy Ibrance (palbociclib) for use on the NHS, the manufacturer has announced that …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
